BOYNTON BEACH, Fla., Nov. 19, 2003 (PRIMEZONE) -- Dr. Jerry I. Jacobson, Chairman, Chief Executive Officer and Chief Science and Technology Officer of Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announces today the publication of successful in-vivo nerve regeneration studies in the journal Medical Hypotheses, Elsevier Science Publishers, 2003 60(6). These data were also presented at international scientific symposia in Russia, Switzerland, Spain, Canada, Sweden, Mexico, Monaco, India, and in the USA.
Essentially, the mouse model used was divided into three groups of statistically significant populations. One group was left alone as the control. One group was poisoned with a neurotoxic agent and not treated. The third group was poisoned and then treated with the Jacobson Resonator. Dr. Jacobson supplied the electromagnetic signals. Among the outcome measures included were forelimb grip strength measurement and photographs taken with an electron microscope. In this study the effectiveness of extremely low intensities and frequencies of electromagnetic fields was clearly demonstrated by the restoration of sub-cellular structures (myelin sheath, mitochondria, golgi bodies, microtubules and neurofilaments) in mice with motor neuropathy and significant grip strength recovery was sustained up to the 27th week of observation; the duration of the study.
While these aforementioned studies, and in-vivo studies, focused upon the radial and sciatic nerves of mice, respectfully, (peripheral nerves) there is the hope that similar approaches may affect the central nervous system. Other researchers have initiated preliminary rigorous scientific studies, with the Jacobson Resonator, involving central nervous system tissues. Furthermore, reports of successful clinical trials in epilepsy, Parkinson's disease, multiple sclerosis, and Alzheimer's disease utilizing pico-Tesla range magnetic fields have been published. Additionally, no side effects were reported.
"I am grateful that scientific studies by world-class scientists have shown that our technology has potential in neuroscience, indeed in neurology. There are many neuro degenerative disorders that might be amenable to such a non-invasive and safe approach. We look forward to conducting neurological studies in the near future in the Caribbean, among other places to probe the various possibilities," said Dr. Jerry I. Jacobson.
Harvey Grossman, President and Chief Strategic Officer states, "We plan on conducting further laboratory experiments in the nerve repair and re-growth area. We also foresee in the coming years conducting double blind clinical trials for FDA, The European Union and Health Canada clearances and approvals in such indications as multiple sclerosis, epilepsy, Parkinson's, Alzheimer's and more. Upon receiving clearances, new treatment markets will be open to our patented technology."
Illustration: It is also our desire to execute double blind randomized placebo controlled studies in Europe and in the USA for the amelioration of Alzheimer's disease in 2006/2007. The Alzheimer's Association estimates that four and one half million Americans (1% of the population at age 65 and 10% over 65) suffer from this devastating disease. Societal costs surrounding Alzheimer's are estimated by the Association to be at least 100 billion dollars annually in the USA. The percentage of afflicted is similar in the European Union and associated countries (23 countries and 600,000,000 people) with nearly nine million people affected. The cost for European society is estimated to be at least 200 billion dollars annually. If approved for treatment, revenues may modestly begin to flow in 2008.
Upon FDA, EU and Health Canada clearances and approvals, our goal is to penetrate 3% to 5% of the market segment for each indication within 10 years of clearance. (1)
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
(1) Although we have set what we believe is a responsible goal there is no assurance that we will achieve this anticipated market penetration. We recognize that there is competition in this marketplace, and that to achieve our goal, we will need to establish significant revenue streams to avoid the need for additional funding, as well as FDA, EU and Health Canada clearances for certain applications of our resonator technology.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances.